Multicenter phase II study of weekly paclitaxel plus S-1 combination chemotherapy in patients with advanced gastric cancer

被引：40

作者：

Ueda, Yuji ^{[1
,2
]}

Yamagishi, Hisakazu ^{[1
]}

Ichikawa, Daisuke ^{[1
]}

Okamoto, Kazuma ^{[1
]}

Otsuji, Eigo ^{[1
]}

Morii, Jun ^{[3
]}

Koizumi, Kinya ^{[3
]}

Kakihara, Naoki ^{[4
]}

Shimotsuma, Masataka ^{[4
]}

Yamashita, Tetsuro ^{[5
]}

Taniguchi, Fumihiro ^{[5
]}

Aragane, Hideki ^{[6
]}

Nishi, Hiroshi ^{[7
]}

Itokawa, Yoshiki ^{[2
]}

Morita, Satoshi ^{[8
]}

Sakamoto, Junichi ^{[9
]}

机构：

[1] Kyoto Prefectural Univ Med, Dept Surg, Div Digest Surg, Kyoto 602, Japan

[2] Nantan Gen Hosp, Dept Surg, Kyoto 6290197, Japan

[3] Natl Hosp Org Kyoto Med Ctr, Dept Surg, Kyoto, Japan

[4] Kyoto Second Red Cross Hosp, Dept Surg, Kyoto, Japan

[5] Kyoto First Red Cross Hosp, Dept Surg, Kyoto, Japan

[6] Aiseikai Yamashina Hosp, Dept Surg, Kyoto, Japan

[7] Saiseikai Kyoto Hosp, Dept Surg, Kyoto, Japan

[8] Yokohama City Univ, Med Ctr, Dept Biostat & Epidemiol, Kanagawa, Japan

[9] Nagoya Univ, Grad Sch Med, Young Leaders Program, Aichi, Japan

来源：

GASTRIC CANCER | 2010年 / 13卷 / 03期

关键词：

Weekly paclitaxel; S-1; Phase II study; Gastric cancer; V-325; STUDY-GROUP; CELL-LINES; BIWEEKLY PACLITAXEL; SUPPORTIVE CARE; FOLINIC ACID; SOLID TUMORS; LUNG-CANCER; 5-FLUOROURACIL; TRIAL; CISPLATIN;

D O I：

10.1007/s10120-010-0548-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background. A multicenter phase II study was conducted to evaluate the efficacy and safety of a combination regimen of weekly paclitaxel plus S-1 in patients with advanced gastric cancer. Methods. Patients with previously untreated metastatic or recurrent gastric cancer received intravenous paclitaxel 50 mg/m(2) on days 1, 8, and 15, plus oral S-1 40 mg/m(2) b.i.d. on days 1 to 14 followed by 2 weeks off, in a 28-day cycle. Results. A total of 54 patients were registered. All of them had measurable disease and were determined to be eligible for the present study. Two complete responses and 23 partial responses were confirmed, giving an overall response rate of 46.3%. At a final follow up of 3 years, the median progression-free survival and median overall survival were 6.0 and 14.3 months, respectively. Grade 3 neutropenia occurred in 14 patients, and grade 4 in 1 patient (total, 27.8%). The most serious nonhematological toxicity was diarrhea, where grade 3 occurred in 5 patients (9.3%). There were no treatment-related deaths. Conclusion. A combination of weekly paclitaxel plus S-1 was found to be well tolerated and effective in patients with advanced gastric cancer. Further investigation with comparative trials is needed for confirmation.

引用

页码：149 / 154

页数：6

共 40 条

[1] Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma [J].

Ajani, JA ;

Lec, FC ;

Singh, DA ;

Haller, DG ;

Lenz, HJ ;

Benson, AB ;

Yanagilhara, R ;

Phan, AT ;

Yao, JC ;

Strumberg, D .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (04) :663-667

[2]

Ajani JA, 1998, CANCER J SCI AM, V4, P269

[3] Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: The V-325 study group [J].

Ajani, Jaffer A. ;

Moiseyenko, Vladimir M. ;

Tjulandin, Sergei ;

Majlis, Alejandro ;

Constenla, Manuel ;

Boni, Corrado ;

Rodrigues, Adriano ;

Fodor, Miguel ;

Chao, Yee ;

Voznyi, Edouard ;

Awad, Lucile ;

Van Cutsem, Eric .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (22) :3210-3216

[4] Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: The V-325 study group [J].

Ajani, Jaffer A. ;

Moiseyenko, Vladimir M. ;

Tjulandin, Sergei ;

Majlis, Alejandro ;

Constenla, Manuel ;

Boni, Corrado ;

Rodrigues, Adriano ;

Fodor, Miguel ;

Chao, Yee ;

Voznyi, Edouard ;

Marabotti, Cindy ;

Van Cutsem, Eric .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (22) :3205-3209

[5] Weekly, high-dose paclitaxel in advanced lung carcinoma - A phase II study with pharmacokinetics by the cancer and leukemia group B [J].

Akerley, W ;

Herndon, JE ;

Egorin, MJ ;

Lyss, AP ;

Kindler, HL ;

Savarese, DM ;

Sherman, CA ;

Rosen, DM ;

Hollis, D ;

Ratain, MJ ;

Green, MR .

CANCER, 2003, 97 (10) :2480-2486

[6] A phase II trial of paclitaxel and weekly 24 h infusion of 5-fluorouracil folinic acid in patients with advanced gastric cancer [J].

Bokemeyer, C ;

Lampe, CS ;

Clemens, MR ;

Hartmann, JT ;

Quietzsch, D ;

Forkmann, L ;

Kollmannsberger, C ;

Kanz, L .

ANTI-CANCER DRUGS, 1997, 8 (04) :396-399

[7] Phase II trial with S-1 in chemotherapy-naive patients with gastric cancer.: A trial performed by the EORTC Early Clinical Studies Group (ECSG) [J].

Chollet, P ;

Schöffski, P ;

Weigang-Köhler, K ;

Schellens, JHM ;

Cure, H ;

Pavlidis, N ;

Grünwald, V ;

De Boer, R ;

Wanders, J ;

Fumoleau, P .

EUROPEAN JOURNAL OF CANCER, 2003, 39 (09) :1264-1270

[8] Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies [J].

Chu, QSC ;

Hammond, LA ;

Schwartz, G ;

Ochoa, L ;

Rha, SY ;

Denis, L ;

Molpus, K ;

Roedig, B ;

Letrent, SP ;

Damle, B ;

DeCillis, AP ;

Rowinsky, EK .

CLINICAL CANCER RESEARCH, 2004, 10 (15) :4913-4921

[9] Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer [J].

Fujitani, K ;

Narahara, H ;

Takiuchi, H ;

Tsujinaka, T ;

Satomi, E ;

Gotoh, M ;

Hirao, M ;

Furukawa, H ;

Taguchi, T .

ONCOLOGY, 2005, 69 (05) :414-420

[10]

Fujiwara Yoshiyuki, 2006, Gan To Kagaku Ryoho, V33, P45

← 1 2 3 4 →